Saturday, April 25, 2009

What's new for 'Trypanosomatids' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message:

Sent on Saturday, 2009 Apr 25
Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.



PubMed Results
Items 1 -9 of 9

1: Indian J Pediatr. 2009 Apr 23. [Epub ahead of print]Click here to read

Multiple relapses of visceral leishmaniasis in a patient treated with liposomal amphotericin.

Akin M, Polat A, Balci YI, Kaya B, Karaca A, Turk M.

Department of Pediatric Haematology, Pamukkale University, Postal Code-20100, Denizli, Turkey, drmakin80@hotmail.com.

PMID: 19390805 [PubMed - as supplied by publisher]

2: Rev Inst Med Trop Sao Paulo. 2009 Mar-Apr;51(2):87-94.Click here to read

Comparison of small mammal prevalence of Leishmania (Leishmania) mexicana in five foci of cutaneous leishmaniasis in the State of Campeche, Mexico.

Van Wynsberghe NR, Canto-Lara SB, Sosa-Bibiano EI, Rivero-Cárdenas NA, Andrade-Narváez FJ.

Laboratorio de Inmunología, Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, Yucatán, México. nvan@tunku.uady.mx

In the Yucatan Peninsula of Mexico, 95% of the human cases of Cutaneous Leishmaniasis are caused by Leishmania (Leishmania) mexicana with an incidence rate of 5.08 per 100,000 inhabitants. Transmission is limited to the winter months (November to March). One study on wild rodents has incriminated Ototylomys phyllotis and Peromyscus yucatanicus as primary reservoirs of L. (L.) mexicana in the focus of La Libertad, Campeche. In the present study, the prevalence of both infection and disease caused by L. (L.) mexicana in small terrestrial mammals were documented during five transmission seasons (1994-2004) in five foci of Leishmaniasis in the state of Campeche. Foci separated by only 100 km, with similar relative abundances of small mammals, were found to differ significantly in their prevalence of both symptoms and infection. Transmission rates and reservoir species seemed to change in space as well as in time which limited the implementation of effective control measures of the disease even in a small endemic area such as the south of the Yucatan Peninsula.

PMID: 19390737 [PubMed - in process]

3: Rev Inst Med Trop Sao Paulo. 2009 Mar-Apr;51(2):83-6.Click here to read

Immunoperoxidase technique using an anti-Leishmania (L.) chagasi hyperimmune serum in the diagnosis of culture-confirmed American tegumentary leishmaniasis.

Quintella LP, Cuzzi T, Madeira Mde F, Okamoto T, Schubach Ade O.

Departamento de Patologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ. Brasil. leonardo.quintella@ipec.fiocruz.br

The present study reports the production of the rabbit anti-Leishmania (L.) chagasi hyperimmune serum, the standardization of the immunohistochemistry (IHC) technique and the evaluation of its employment in cutaneous leishmaniasis (CL) lesions diagnosed by Leishmania sp. culture isolation. Thirty fragments of active CL lesions were examined as well as 10 fragments of cutaneous mycosis lesions as control group. IHC proved more sensitive in detecting amastigotes than conventional hematoxylin-eosin (HE) stained slides: the former was positive in 24 (80%) biopsies whereas the latter, in 16 (53%) (p = 0.028). The reaction stained different fungus species causing cutaneous mycosis. Besides, positive reaction was noticed in mononuclear and endothelial cells. Nevertheless, this finding was present in the control group biopsies. It is concluded that IHC showed good sensitivity in detecting amastigotes.

PMID: 19390736 [PubMed - in process]

4: Parasite Immunol. 2009 May;31(5):254-66.Click here to read

Genetics and visceral leishmaniasis: of mice and man.

Blackwell JM, Fakiola M, Ibrahim ME, Jamieson SE, Jeronimo SB, Miller EN, Mishra A, Mohamed HS, Peacock CS, Raju M, Sundar S, Wilson ME.

Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Western Australia, Australia. jblackwell@ichr.uwa.edu.au

Ninety per cent of the 500,000 annual new cases of visceral leishmaniasis (VL) occur in India/Bangladesh/Nepal, Sudan and Brazil. Importantly, 80-90% of human infections are sub-clinical or asymptomatic, usually associated with strong cell-mediated immunity. Understanding the environmental and genetic risk factors that determine why two people with the same exposure to infection differ in susceptibility could provide important leads for improved therapies. Recent research using candidate gene association analysis and genome-wide linkage studies (GWLS) in collections of families from Sudan, Brazil and India have identified a number of genes/regions related both to environmental risk factors (e.g. iron), as well as genes that determine type 1 vs. type 2 cellular immune responses. However, until now all of the allelic association studies carried out have been underpowered to find genes of small effect sizes (odds ratios or OR < 2), and GWLS using multicase pedigrees have only been powered to find single major genes, or at best oligogenic control. The accumulation of large DNA banks from India and Brazil now makes it possible to undertake genome-wide association studies (GWAS), which are ongoing as part of phase 2 of the Wellcome Trust Case Control Consortium. Data from this analysis should seed research into novel genes and mechanisms that influence susceptibility to VL.

PMID: 19388946 [PubMed - in process]

5: J Nat Prod. 2009 Apr;72(4):745-8.Click here to read

Trinorsesquiterpenoids from the root extract of Pentalinon andrieuxii.

Yam-Puc A, Escalante-Erosa F, Pech-López M, Chan-Bacab MJ, Arunachalampillai A, Wendt OF, Sterner O, Peña-Rodríguez LM.

Centro de Investigación Científica de Yucatán, Merida, Yucatán, Mexico.

Two unusual trinorsesquiterpenoids, urechitols A (1) and B (2), were isolated from the root extract of Pentalinon andrieuxii, a plant used commonly in Yucatecan traditional medicine to treat leishmaniasis. The structures of 1 and 2 were identified by interpretation of their spectroscopic data and chemical correlation reactions. The relative stereochemistry of 1 was confirmed through an X-ray crystallographic study.

PMID: 19388707 [PubMed - in process]

6: Bull Soc Pathol Exot. 2009 Feb;102(1):3-4.LinkOut

[Chagas disease at one hundred years]

[Article in French]

Pays JF.

PMID: 19343908 [PubMed - indexed for MEDLINE]

7: Vaccine. 2009 Feb 25;27(9):1323-32. Epub 2009 Jan 20.Click here to read LinkOut

Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library.

Tekiel V, Alba-Soto CD, González Cappa SM, Postan M, Sánchez DO.

Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, CONICET, Buenos Aires, Argentina. valet@iib.unsam.edu.ar

The protozoan Trypanosoma cruzi is the etiological agent of Chagas' disease, a major chronic infection in Latin America. Currently, there are neither effective drugs nor vaccines for the treatment or prevention of the disease. Several T. cruzi surface antigens are being tested as vaccines but none of them proved to be completely protective, probably because they represent only a limited repertoire of all the possible T. cruzi target molecules. Taking into account that the trypomastigote stage of the parasite must express genes that allow the parasite to disseminate into the tissues and invade cells, we reasoned that genes preferentially expressed in trypomastigotes represent potential targets for immunization. Here we screened an epimastigote-subtracted trypomastigote cDNA expression library by genetic immunization, in order to find new vaccine candidates for Chagas' disease. After two rounds of immunization and challenge with trypomastigotes, this approach led to the identification of a pool of 28 gene fragments that improved in vivo protection. Sequence analysis of these putative candidates revealed that 19 out of 28 (67.85%) of the genes were hypothetical proteins or unannotated T. cruzi open reading frames, which certainly would not have been identified by other methods of vaccine discovery.

PMID: 19162108 [PubMed - indexed for MEDLINE]

8: Heart. 2009 Apr;95(7):524-34. Epub 2009 Jan 8.Click here to read LinkOut

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease.

Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A.

Anis Rassi Hospital, Setor Oeste, Goiania, Brazil. arassijr@terra.com.br

A century after its discovery, Chagas' disease still represents a major public health challenge in Latin America. Moreover, because of growing population movements, an increasing number of cases of imported Chagas' disease have now been detected in non-endemic areas, such as North America and some European countries. This parasitic zoonosis, caused by Trypanosoma cruzi, is transmitted to humans by infected Triatominae insects, or occasionally by non-vectorial mechanisms, such as blood transfusion, mother to fetus, or oral ingestion of materials contaminated with parasites. Following the acute phase of the infection, untreated individuals enter a chronic phase that is initially asymptomatic or clinically unapparent. Usually, a few decades later, 40-50% of patients develop progressive cardiomyopathy and/or motility disturbances of the oesophagus and colon. In the last decades several interventions targeting primary, secondary and tertiary prevention of Chagas' disease have been attempted. While control of both vectorial and blood transfusion transmission of T cruzi (primary prevention) has been successful in many regions of Latin America, early detection and aetiological treatment of asymptomatic subjects with Chagas' disease (secondary prevention) have been largely underutilised. At the same time, in patients with established chronic disease, several pharmacological and non-pharmacological interventions are currently available and have been increasingly used with the intention of preventing or delaying complications of the disease (tertiary prevention). In this review we discuss in detail each of these issues.

PMID: 19131444 [PubMed - indexed for MEDLINE]

9: Rev Med Chil. 2008 Jul;136(7):945-6. Epub 2008 Sep 4.Click here to read LinkOut

[Chagas disease in the rural area of Metropolitan Region (Santiago) and V Region (Aconcagua), Chile]

[Article in Spanish]

Lorca M, Soto F, Soto P, Padilla G, Núñez E, Rojas J, Horta M, Bustamante M, Atencio J, Raychaudhuri S.

PMID: 18949173 [PubMed - indexed for MEDLINE]

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)